PDCD1 and melanoma: It also exhibited a significant enhancement of IFN-γ production of the PD-1 KO groups (melanoma patient: MAGE-A1, p = 0.0053; Tyrosine, p = 0.0163; gp100, p = 0.0149; GV1001, p = 0.0022; MAGE-A2, p = 0.1499; MAGE-A3, p = 0.1168) (Fig. 6c); (gastric cancer patient : CEA571, p = 0.0519; CEA691, p = 0.0209; CA125, p = 0.0035; Survivin, p = 0.0008; Muc-1, p = 0.0176) (Fig. 6d).